柠萌影视(09857.HK)发布公告，预期：(i)集团2025年上半年取得净利润约人民币1000万元至人民币1200 万元，而2024年6月30日止六个月取得净亏损约人民币5290万元;及(ii)集团2025年上半年取得经调整净利 润约人民币1300万元至人民币1500万元，而2024年6月30日止六个月取得经调整净亏损约人民币4940万 元，因此净利润及经调整净利润均实现转亏为盈。 ...

公告称，集团2025年上半年净利润及经调整净利润实现转亏为盈的主要原因为优质版权剧播出带动收入 增长、短剧等新业务的财务表现改善，以及进一步深化全面预算管理带动提质增效及费用优化等。 柠萌影视(09857)发布公告，预期：(i)集团2025年上半年取得净利润约人民币1000万元至人民币1200万 元，而2024年6月30日止六个月取得净亏损约人民币5290万元;及(ii)集团2025年上半年取得经调整净利润 约人民币1300万元至人民币1500万元，而2024年6月30日止六个月取得经调整净亏损约人民币4940万 元，因此净利润及经调整净利润均实现转亏为盈。 ...

格隆汇8月6日丨柠萌影视(09857.HK)发布公告，2025年上半年，预期：(i)集团2025年上半年录得净利润 约人民币1000万元至人民币1200万元，而2024年6月30日止六个月录得净亏损约人民币5290万元；及(ii) 集团2025年上半年录得经调整净利润约人民币1300万元至人民币1500万元，而2024年6月30日止六个月 录得经调整净亏损约人民币4940万元，因此净利润及经调整净利润均实现转亏为盈。 董事会认为，集团2025年上半年净利润及经调整净利润实现转亏为盈的主要原因为优质版权剧播出带动 收入增长、短剧等新业务的财务表现改善，以及进一步深化全面预算管理带动提质增效及费用优化等。 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 檸萌影視傳媒有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09857 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 2,000,000,000 | USD | | 0.000025 | USD | | 50,000 | 本月底法定/註冊股本 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Linmon Media Limited 股東及潛在投資者於買賣本公司股份時，務請審慎行事。 9857 正面盈利預告 本公告乃由檸萌影視傳媒有限公司（「本公司」，連同其附屬公司及併表聯屬實體統稱為 「本集團」）根據香港聯合交易所有限公司證券上市規則（「上市規則」）第13.09條及香港法例 第571章證券及期貨條例第XIVA部項下內幕消息條文（定義見上市規則）刊發。 本公司董事會（「董事會」）謹此知會本公司股東（「股東」）及潛在投資者，根據本集團截至 2025年6月30日止六個月（「2025年上半年」）未經審核之綜合管理賬目及現時可得資料所作 出之初步評估，預期：(i)本集團2025年上半年錄得淨利潤約人民幣10.0百萬元至人民幣 12.0百萬元，而2024年6月30日止六個月錄得淨虧損約人民幣52.9百萬元；及(ii)本集團 2025年上半年錄得經調整淨利潤約人民幣13.0百萬元至人民幣15.0百萬元， ...

Company Overview - CMC (柠萌影视) is a leading content production company in China, focusing on high-quality drama series based on a strong copyright IP reserve [2] - Since its establishment in 2014, CMC has produced and released 13 high-quality drama series, achieving a high quality rate of approximately 71.4% [2] - The company has explored new growth channels such as content marketing, derivative licensing, and overseas distribution to maximize the commercial value of its proprietary IP [2] Financial Performance - As of December 31, 2024, CMC reported total revenue of 657 million yuan, a year-on-year decrease of 46.22% [1] - The company recorded a net loss attributable to shareholders of 189 million yuan, a year-on-year decrease of 188.54% [1] - CMC's gross profit margin stands at 16.52%, with a debt-to-asset ratio of 28.09% [1] Market Position - CMC's current price-to-earnings (P/E) ratio is -5.56, ranking 79th in the media and entertainment industry, which has an average P/E ratio of -13.52 [1] - The company has underperformed the Hang Seng Index, with a year-to-date increase of 12.14%, compared to the index's increase of 20.38% [1] - No investment ratings have been issued by institutions for CMC at this time [1]

Industry Overview - The current state of the drama market is challenging, with only a few shows like "In the Name of the Law" performing reasonably well, while others from major production companies have not made a significant impact [1][9] - The first phase of the summer season has concluded with disappointing results for major players, as many anticipated dramas failed to resonate with audiences [9] Key Productions and Performances - Tencent Video and iQIYI launched "Lychee of Chang'an" and "Lingjiang Xian" respectively, but both shows faced content controversies that hindered their success despite strong production teams [1][3] - Notable dramas such as "The Age of Forging" and "Huan Yu" also struggled, failing to meet audience expectations due to weak storytelling and character development [3][6] - The summer drama landscape is expected to become more competitive as new productions are set to debut, including "Justifiable Defense," which focuses on self-defense cases and features a strong cast [10][12] Upcoming Projects - Several new dramas are scheduled for release, including "Justifiable Defense" on July 9, which is anticipated to be a standout due to its unique theme and high-profile cast [10][12] - New productions from established companies like New Classics Media and Zhengwu Media are also on the horizon, with a variety of genres being explored [14][18] - The upcoming dramas from Noon Sunshine and Lingmeng are expected to contribute to the summer lineup, with "Cherry Amber" and "Midnight Return" respectively [14][16] Market Trends - Compared to the same period last year, the overall quality of summer dramas has declined, with no standout series capturing a wide audience [20] - The industry is looking for high-quality productions to emerge in the coming months to reverse the current downward trend [20]

Core Insights - The core viewpoint of the article is the announcement of the 2025 drama series lineup by Lingmeng Media, featuring seven new productions that will begin filming in the second half of the year, showcasing the company's strong content creation capabilities and forward-looking strategy [1][17][20]. Group 1: Overview of the 2025 Drama Series - Lingmeng Media's 2025 lineup includes seven works: "Confrontation," "Ask the Heart 2," "Small Town Good Prescription," "A Thought of Jiangnan," "Just in Time for Rain," "Today is Sun Rain," and "Ten Days to the End" [1][17]. - The series spans various genres, including realism, contemporary romance, historical drama, and fantasy, reflecting the company's diverse storytelling approach [17][20]. Group 2: Key Productions and Themes - "Confrontation," a key project guided by the Ministry of National Security, focuses on national security and human nature, marking the first domestic series to address cross-strait relations and Sino-U.S. dynamics [18]. - "Ask the Heart 2" continues the story from its first season, featuring the same creative team and exploring themes of warmth and hope in the medical field [18]. - "Small Town Good Prescription" tells the story of a genius doctor facing life's challenges and finding a "second-best solution" upon returning to his hometown [18]. Group 3: Industry Position and Strategy - Despite facing industry-wide challenges and a projected loss in 2024, Lingmeng Media is increasing production capacity, leveraging its strong cash flow and stable financial position to invest in high-quality content [20]. - The company plans to produce over 200 episodes this year, including additional films and short dramas, reinforcing its commitment to high-quality content creation [20]. - Lingmeng Media emphasizes its belief in the importance of good content and aims to be a nurturing environment for talented creators, focusing on producing works that resonate with audiences and reflect societal values [20].

Group 1 - Hong Kong film stocks have strengthened, with Ningmeng Film (09857.HK) rising over 20% [1] - Alibaba Pictures (01060.HK) increased nearly 7% [1] - Other companies such as Lehua Group (02306.HK) and One Universe (01616.HK) also saw gains [1]

Group 1 - The Hong Kong film and television stocks are performing strongly, with Alibaba Pictures (01060.HK) rising over 5% [1] - Bigo Group (08220.HK) has increased by more than 2% [1] - Other companies such as Maoyan Entertainment (01896.HK) and Ningmeng Pictures (09857.HK) also saw gains [1]